Identification of a RIP1 Kinase Inhibitor Clinical Candidate (GSK3145095) for the Treatment of Pancreatic Cancer

Area of Science:

• Molecular biology
• Oncology
• Immunology

Background:

• Receptor-interacting protein 1 (RIP1) kinase is crucial in regulating cell death and inflammation, implicated in various pathologies like cancer and inflammatory diseases.
• While RIP1 kinase inhibitors exist for inflammatory and CNS conditions, none have been developed for oncology indications.
• Targeting RIP1 kinase offers a potential therapeutic strategy for cancers driven by its signaling pathways.

Purpose of the Study:

• To discover and characterize novel small-molecule inhibitors of RIP1 kinase for oncology.
• To evaluate the efficacy of a newly identified RIP1 inhibitor, GSK3145095 (compound 6), in preclinical cancer models.
• To assess the compound's potential to modulate the tumor microenvironment and T cell responses.

Main Methods:

• Chemical synthesis and profiling of small molecules targeting RIP1 kinase.
• In vitro kinase assays to determine potency and specificity of compound 6.
• Cellular assays to assess inhibition of RIP1 kinase-dependent signaling.
• Organotypic culture models of pancreatic adenocarcinoma to evaluate anti-tumor effects and T cell modulation.

Main Results:

• GSK3145095 (compound 6) demonstrated potent and specific inhibition of RIP1 kinase activity.
• The compound effectively blocked RIP1 kinase-dependent cellular responses in vitro.
• Compound 6 promoted a tumor-suppressive T cell phenotype in pancreatic adenocarcinoma organ cultures.
• Preclinical data support the potential of compound 6 as a novel cancer therapeutic.

Conclusions:

• GSK3145095 (compound 6) is a potent and specific RIP1 kinase inhibitor with demonstrated anti-cancer potential.
• The compound's ability to modulate T cell responses suggests a dual mechanism of action in cancer therapy.
• Compound 6 is currently undergoing phase 1 clinical trials for pancreatic adenocarcinoma and other solid tumors, highlighting its therapeutic promise.